Fighting neurodegeneration with rapamycin: mechanistic insights

@article{Bov2011FightingNW,
  title={Fighting neurodegeneration with rapamycin: mechanistic insights},
  author={Jordi Bov{\'e} and Marta Mart{\'i}nez-Vicente and Miquel Vila},
  journal={Nature Reviews Neuroscience},
  year={2011},
  volume={12},
  pages={437-452}
}
A growing number of studies point to rapamycin as a pharmacological compound that is able to provide neuroprotection in several experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3. In addition, rapamycin exerts strong anti-ageing effects in several species, including mammals. By inhibiting the activity of mammalian target of rapamycin (mTOR), rapamycin influences a variety of essential… Expand
It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (rapamycin)
TLDR
Research is needed to uncover more specific inhibitors of particular mTOR signaling pathways, and to establish realistic guidelines for treatment at early stages of neurodegenerative processes. Expand
A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy
The role of autophagy in supporting cellular survival and inhibiting neurodegeneration in Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, which are accompanied by the accumulationExpand
Rapamycin, Autophagy, and Alzheimer's Disease.
TLDR
Rapamycin enhancement of autophagy has been associated with abrogation of AD pathological processes such as clearance of Aβ and neurofibrillary tangles (NTFs) as well as reduction of tau hyper-phosphorylation and improvement of cognition, and rapamycin is emerging as a potential therapeutic compound for AD. Expand
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
TLDR
Three pathways that represent prominent mechanisms linking GSK-3 with neurodegenerative disorders: cytoskeleton organization, the mammalian target of rapamycin (mTOR)/autophagy axis, and mitochondria are focused on. Expand
Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration
TLDR
It is concluded that MPC is a novel and potentially powerful therapeutic target that warrants further study in attempts to slow Parkinson’s disease progression. Expand
Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities
TLDR
Unravelling the molecular mechanisms involved in HD pathogenesis of proteostasis provides new insight in disease progression in HD as well as possible therapeutic avenues. Expand
Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer’s disease
TLDR
GPCR-mediated modulation of mTOR may take advantage of different GPCRs coupled to different G-dependent and G-independent signal transduction routes, of functional selectivity and/or of biased agonism to achieve different benefits in different stages of the neurodegenerative disease. Expand
The Neurology of mTOR
TLDR
The functions of mTOR signaling in the normal and pathological brain are reviewed, highlighting ongoing efforts to translate the understanding of cellular physiology into direct medical benefit for neurological disorders. Expand
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
TLDR
The targeted manipulation of downstream ALP components, rather than broad autophagy stimulation, may be an attractive strategy for the development of novel pharmacological therapies in PD. Expand
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
  • M. Wong
  • Biology, Medicine
  • Biomedical journal
  • 2013
TLDR
The mammalian target of rapamycin (mTOR) pathway is an essential cellular signaling pathway involved in a number of important physiological functions, including cell growth, proliferation, metabolism, protein synthesis, and autophagy, which is involved in developmental disorders and neurodegenerative diseases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 199 REFERENCES
TOR on the brain
TLDR
This work reviews mTOR signaling and how neurons utilize mTOR to regulate brain function, including regulation of feeding, synaptic plasticity and memory formation, and discusses recent findings that evaluate the mechanisms by which reduced mTOR activity might benefit the aging brain in normal and pathological states. Expand
Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies
TLDR
Various drugs and pathways inducing autophagy, which may be potential therapeutic approaches for Huntington's disease and related conditions are described. Expand
Neurological diseases: Targeting programmed cell death in neurodegenerative diseases
TLDR
To identify potential neuroprotective targets within the PCD machinery, the expression and activity of some of its components have been altered by genetic or pharmacological means in experimental models of neurodegenerative diseases. Expand
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
TLDR
Overall, available data support the importance of non-cell-autonomous pathological mechanisms in Parkinson's disease, which are mostly mediated by activated glial and peripheral immune cells. Expand
Rapamycin alleviates toxicity of different aggregate-prone proteins.
TLDR
The studies suggest that the scope for rapamycin as a potential therapeutic in aggregate diseases may be much broader than HD or even polyglutamine diseases. Expand
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
TLDR
Proof of principle is demonstrated for a new approach for discovery of small-molecule modulators of mammalian autophagy for therapeutic potential in Huntington's disease cell and Drosophila melanogaster models. Expand
Autophagy gone awry in neurodegenerative diseases
TLDR
Examples of different types of autophagic dysfunction described in common neurodegenerative disorders are presented and the prospect of exploring some of the recently identified Autophagic variants and the interactions among autphagic and non-autophagic proteolytic systems as possible future therapeutic targets are discussed. Expand
Rapamycin is a neuroprotective treatment for traumatic brain injury
TLDR
Rapamycin is neuroprotective following traumatic brain injury and as a drug used in the clinic for other indications, it is proposed that further studies on rapamycin should be conducted in order to consider it as a novel therapy for traumatic head injury. Expand
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
TLDR
It is shown that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Aβ42, a major toxic species in AD, in the PDAPP transgenic mouse model. Expand
Rapamycin Inhibits Polyglutamine Aggregation Independently of Autophagy by Reducing Protein Synthesis
TLDR
It is shown that rapamycin reduces the amount of soluble polyQ protein via a modest inhibition of protein synthesis that in turn significantly reduces the formation of insoluble polyQprotein and IB formation, suggesting that rap amycin may alleviate polyQ disease pathology via its effect on global protein synthesis. Expand
...
1
2
3
4
5
...